- Ginkgo Bioworks (DNA, Financial) launches a high-throughput ADME profiling service using proprietary RAC automation technology.
- The service offers U.S.-based operations with price matching against international vendors, including Chinese competitors.
- Features include scalable automated workflows, rapid turnaround times, and AI-compatible datasets to accelerate drug discovery.
Ginkgo Bioworks (DNA), a leader in cell programming and biosecurity, has unveiled a new high-throughput ADME (Absorption, Distribution, Metabolism, and Excretion) profiling service. Leveraging its proprietary RAC automation technology, this service is designed to accelerate small molecule drug discovery by providing cost-competitive ADME testing within the United States, challenging international vendors on price, including those from China.
The newly launched service promises automated workflows, ensuring rapid turnaround times, and AI-compatible datasets to help researchers efficiently prioritize drug candidates. By matching or beating international pricing, Ginkgo aims to provide an affordable, robust solution to the biopharma industry while maintaining operations within the U.S.
Jason Kelly, co-founder and CEO of Ginkgo Bioworks, highlighted the potential of this service as a transformative force in drug discovery, emphasizing their commitment to competitive pricing and the high quality of their offerings. Ginkgo's move to offer these enhanced services reflects their strategic expansion into the pharmaceutical services market, aligning with trends in high-throughput drug discovery and machine learning-based predictive modeling.
